Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Marksans Pharma's Enterprise Value is ₹116,568 Mil.
Marksans Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5,847 Mil. Therefore, Marksans Pharma's EV-to-EBIT ratio for today is 19.94.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Marksans Pharma's Enterprise Value is ₹116,568 Mil.
Marksans Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6,833 Mil. Therefore, Marksans Pharma's EV-to-EBITDA ratio for today is 17.06.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Marksans Pharma's Enterprise Value is ₹116,568 Mil.
Marksans Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹29,509 Mil. Therefore, Marksans Pharma's EV-to-Revenue ratio for today is 3.95.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Marksans Pharma (BOM:524404) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Marksans Pharma's current Enterprise Value is ₹116,568 Mil.
Marksans Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,847 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Marksans Pharma's current Enterprise Value is ₹116,568 Mil.
Marksans Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,833 Mil.
Marksans Pharma's current Enterprise Value is ₹116,568 Mil.
Marksans Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹29,509 Mil.
Marksans Pharma's current Enterprise Value is ₹116,568 Mil.
Marksans Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Marksans Pharma's current Enterprise Value is ₹116,568 Mil.
Marksans Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marksans Pharma Enterprise Value Related Terms
Marksans Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524404 vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Marksans Pharma's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₹116,568 Mil mean?
Marksans Pharma (BOM:524404) has a Enterprise Value of ₹116,568 Mil as of Jul. 15, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Marksans Pharma and its competitors.
Is Marksans Pharma's Enterprise Value too high?
Marksans Pharma's current Enterprise Value is ₹116,568 Mil. Overall, Marksans Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Enterprise Value compare to LLY and JNJ?
Marksans Pharma's Enterprise Value of ₹116,568 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Marksans Pharma and its competitors. Marksans Pharma's current Enterprise Value is ₹116,568 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹229.14, compared to a current price of ₹270.85 — trading 18.2% above its estimated fair value. The current Enterprise Value is ₹116,568 Mil. Marksans Pharma's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Enterprise Value is ₹116,568 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹270.85 is trading 18.2% above its estimated GF Value™ of ₹229.14.
GuruFocus considers Marksans Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524404:
Enterprise Value: ₹116,568 Mil
GF Value™: ₹229.14 vs. price of ₹270.85 (18.2% above fair value)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
86GF Score
Get the complete analysis for BOM:524404
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
